Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals

DOI PDF Web Site PubMed 被引用文献5件 オープンアクセス

書誌事項

公開日
2017-03-14
権利情報
  • http://creativecommons.org/licenses/by/4.0/
  • http://creativecommons.org/licenses/by/4.0/
DOI
  • 10.1186/s12916-017-0815-7
公開者
Springer Science and Business Media LLC

説明

Hepatitis C virus infection is a major cause of hepatocellular carcinoma worldwide. Interferon has been the major antiviral treatment, yielding viral clearance in approximately half of patients. New direct-acting antivirals substantially improved the cure rate to above 90%. However, access to therapies remains limited due to the high costs and under-diagnosis of infection in specific subpopulations, e.g., baby boomers, inmates, and injection drug users, and therefore, hepatocellular carcinoma incidence is predicted to increase in the next decades even in high-resource countries. Moreover, cancer risk persists even after 10 years of viral cure, and thus a clinical strategy for its monitoring is urgently needed. Several risk-predictive host factors, e.g., advanced liver fibrosis, older age, accompanying metabolic diseases such as diabetes, persisting hepatic inflammation, and elevated alpha-fetoprotein, as well as viral factors, e.g., core protein variants and genotype 3, have been reported. Indeed, a molecular signature in the liver has been associated with cancer risk even after viral cure. Direct-acting antivirals may affect cancer development and recurrence, which needs to be determined in further investigation.

収録刊行物

  • BMC Medicine

    BMC Medicine 15 (1), 52-, 2017-03-14

    Springer Science and Business Media LLC

被引用文献 (5)*注記

もっと見る

キーワード

問題の指摘

ページトップへ